|
Product Report
|
Multiple Myeloma - Exploring new targets for multiple drug therapy
The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson) has significantly advanced treatment.
|
|
Read more...
|
|
|
Product Report
|
 Innovation in Drug Delivery: The future of nanotechnology and non-invasive protein delivery
Innovation in Drug Delivery provides an in-depth examination of product launches and pipeline drugs with novel drug delivery mechanisms set to revolutionize the market, such as products using ALZA Corporation’s E-TRANS and Altea’s PassPort patch transdermal technologies.
|
|
Read more...
|
|
|
Product Report
|
Next-Generation Nutraceuticals: Food and pharma convergence
Next-Generation Nutraceuticals is a new report published by Business Insights that provides analysis of how the food and pharmaceutical industries are becoming more aligned in their approach to consumer health.
|
|
Read more...
|
|
|
Product Report
|
Innovations in CNS: Novel therapeutics and future RandD strategies
The CNS drug market presents significant profit opportunities, but also carries high risks for companies aiming to achieve blockbuster status.
|
|
Read more...
|
|
|
Product Report
|
Next Generation Protein Engineering & Drug Design: Strategies to boost efficacy
The success of protein and peptide therapeutics is revolutionizing the biotech and pharmaceutical market, spurring the creation of next-generation products with reduced immunogenicity, improved safety and greater effectiveness.
|
|
Read more...
|
|
|
Product Report
|
Winning Product Launch Strategies: Maximizing sales from new pharmaceutical products
With pharmaceutical R&D continuing to suffer from declining productivity levels and stagnant returns on investment, effective, flexible and commercially successful new product launches have become more important than ever.
|
|
Read more...
|
|
|
Product Report
|
Drug Repositioning Strategies: Innovative strategies to boost pipeline productivity
Drug repositioning is regarded as the pharma industry’s solution to falling R&D productivity and weakening product pipelines, successful repositioned drugs such as raloxifene (Evista; Lilly), thalidomide (Thalomid; Celegene), (Exubera;Pfizer/Nektar) have enabledinnovative companies to adopt lower risk strategies to optimize product pipelines.
|
|
Read more...
|
|
|
Product Report
|
Innovative and Targeted Cancer Therapies: Key technologies, new applications and leading players
The highly dynamic cancer market is creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. Resultantly, cancer innovatives are not only the fastest growing segment within the cancer market, but the key drivers of sales growth across the pharmaceutical market as a whole.
|
|
Read more...
|
|
|
Product Report
|
The Future of Biosimilars: Key opportunities & emerging therapies
Biotechnological products are continuing to exhibit substantial revenue gains, with the top 12 biologics registering sales growth of 20%in 2006, amassing a market share of $64 billion. However, the impending patent expiry of many leading products has created a number of highly attractive market opportunities for biosimilars. To exploit this significant potential, a complex route to market must first be negotiated, including numerous barriers to entry and regulatory hurdles.
|
|
Read more...
|
|
|
<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>
|
| Results 352 - 360 of 367 |
Farmavita.Net Journal 
